ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors // Chi-Med
AIM: £34.25 (+0.75) | Nasdaq: $22.25 (+0.30)
News Archive
Previous Article   |   Next Article
Presentations | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors

1 Item
View Poster (JPG)